February 2, 2018—A team of independent health policy experts have questioned the major findings in a recent New England Journal of Medicine (NEJM) study critical of the 340B drug pricing program. In its Jan. 24 issue, the journal published a study authored by Sunita Desai, Ph.D., and J. Michael McWilliams, M.D., Ph.D., that raised questions about whether 340B hospitals are … [Read more...]